Absence of anaplastic lymphoma kinase-1 expression in inflammatory myofibroblastic tumors of the central nervous system: Does it signify a different nosologic entity from its systemic counterpart? | Zendy

Anita Mahadevan | Zendy; Sunil V. Furtado | Zendy; Susarla Krishna | Zendy; Shrijeet Chakraborti | Zendy; Aparna Govindan | Zendy

Open Access

Absence of anaplastic lymphoma kinase-1 expression in inflammatory myofibroblastic tumors of the central nervous system: Does it signify a different nosologic entity from its systemic counterpart?

Author(s) -

Anita Mahadevan,

Sunil V. Furtado,

Susarla Krishna,

Shrijeet Chakraborti,

Aparna Govindan

Publication year - 2014

Publication title -

indian journal of pathology and microbiology

Language(s) - English

Resource type - Journals

eISSN - 0974-5130

pISSN - 0377-4929

DOI - 10.4103/0377-4929.134658

Subject(s) - anaplastic lymphoma kinase , pathology , immunohistochemistry , cd68 , lymphoma , medicine , anaplastic large cell lymphoma , vimentin , immunophenotyping , b cell lymphoma , antigen , immunology , malignant pleural effusion , lung cancer

Inflammatory myofibroblastic tumors (IMFTs) are uncommon neoplasms of the central nervous system (CNS) of intermediate grade biologic potential. Anaplastic lymphoma kinase (ALK-1), a diagnostic marker of anaplastic large cell lymphoma, is also expressed in a subset of IMFTs and appears to have prognostic significance. Though, few studies have evaluated expression of ALK-1 in IMFTs of the CNS. This retrospective study was undertaken to evaluate the expression of ALK-1 expression in IMFT of CNS by immunohistochemistry and correlate with the clinical, radiological and pathologic features.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research